Cipla to further invest Rs 25.90 crore to acquire 22.02% stake in GoApptiv
Strengthens investment in channels of the future to expand patient reach
Strengthens investment in channels of the future to expand patient reach
First and only PARP inhibitor to improve invasive disease-free survival in patients
The Congress was held on June, 20-21, 2022 in Berlin, Germany
By applying digital technologies, pharma companies can significantly improve their operational and decision-making capabilities
The FDA informed Astellas that it did not have sufficient information to assess the risks to subjects
Both vaccine candidates demonstrated a favorable safety and tolerability profile similar to the Pfizer-BioNTech COVID-19 Vaccine
An interim analysis of this data shows no significant safety issues and a 91% seroconversion rate at Day 56.
This new €59 million, 70,000 square foot facility, officially opened today, brings 50 new jobs to the area
This includes USD 100 million to advance R&D of its neglected tropical disease program, focusing on novel drug candidates for four diseases.
Silo enters into commercial evaluation license agreement for next generation liposomes
Subscribe To Our Newsletter & Stay Updated